SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve patient outcomes, announces it
has entered into an agreement with Health Net Federal Services LLC
to be an in-network provider for its Target Selector™
liquid biopsy oncology platform for the TRICARE West (TriWest)
region network. TriWest provides healthcare services to
approximately three million members of the U.S. military and their
families.
"It's an honor to become a provider for TriWest and to support
the healthcare needs of our country's military service members and
their families," said Michael Nall,
President and CEO of Biocept. "Our Target Selector™ platform
can be used to improve treatment outcomes by helping physicians
rapidly obtain the actionable information they need to design
personalized treatment plans for their patients diagnosed with
cancer. Expanding the number of managed care agreements is
among our strategic objectives. Our liquid biopsy platform is
available on an in-network basis to millions of patients across the
U.S. and now we are very proud to include those who are serving our
country as they fight a new battle, this time with cancer."
About TRICARE West Region Network
TRICARE is the
worldwide healthcare program available to eligible beneficiaries of
the seven uniformed services – the Army, U.S. Navy, U.S. Air Force,
U.S. Marine Corps, U.S. Coast Guard, Commissioned Corps of the U.S.
Public Health Service, and the Commissioned Corps of the National
Oceanic and Atmospheric Administration. TRICARE-eligible
beneficiaries may include active duty service members and their
families, retired service members and their families, National
Guard and Reserve members and their families, survivors, certain
former spouses, and others. TRICARE is jointly managed by the
Defense Health Agency (DHA) and the TRICARE Health Plan. The
DHA has partnered with civilian regional contractors in the East
and West regions to assist TRICARE regional directors, and military
hospital and clinic commanders in operating an integrated health
care delivery system
TriWest is managed under a contract with the DHA by Health Net
Federal Services. Coverage includes the states of
Alaska, Arizona, California, Colorado, Hawaii, Idaho, Iowa
(except the Rock Island Arsenal area), Kansas, Minnesota, Missouri (except the St. Louis area), Montana, Nebraska, Nevada, New
Mexico, North Dakota,
Oregon, South Dakota, Texas (areas of Western Texas only), Utah, Washington, and Wyoming. More
information is available at www.tricare-west.com.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept recently added COVID-19 testing to support
efforts to fight the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the ability of our tests to provide clinically
actionable information, and the ability of Biocept's platform to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options, such statements
are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-executes-in-network-provider-agreement-with-health-net-federal-services-extending-coverage-for-its-liquid-biopsy-oncology-platform-to-the-tricare-west-region-network-301124926.html
SOURCE Biocept, Inc.